Spyre Therapeutics | Aeglea BioTherapeutics

Spyre Therapeutics (formerly Aeglea BioTherapeutics) is a clinical-stage biotechnology company focused on developing next-generation antibody therapeutics for inflammatory bowel disease (IBD). Following the 2023 acquisition of Spyre Therapeutics by Aeglea and subsequent rebranding, the company transitioned away from its historical emphasis on engineered human enzymes for rare metabolic diseases to a new focus on immunology-driven therapies with potential best-in-class profiles.

Spyre is building a diversified pipeline of long-acting antibodies designed to target validated pathways in IBD, including anti-α4β7 and anti-TL1A programs. These candidates aim to improve durability, patient convenience, and combination-therapy potential. The company’s business model centers on the discovery, clinical development, and commercialization of innovative biologics that address large, underserved markets in inflammatory disease.

As a clinical-stage company, Spyre Therapeutics does not yet have approved products, and its operations are primarily funded through venture investment, public equity financing, and partnerships. The company serves a significant unmet need within the gastrointestinal therapeutics market, focusing on more effective and durable treatment options for patients with ulcerative colitis and Crohn’s disease.

The company’s legacy rare-disease enzyme program—pegzilarginase for Arginase 1 Deficiency—has been deprioritized following the strategic shift and is now maintained only as part of historical Aeglea development activities.

Keywords: biotechnology, antibody therapeutics, inflammatory bowel disease, immunology, TL1A, α4β7, clinical-stage biopharmaceutical, ulcerative colitis, Crohn’s disease, drug development, Spyre Therapeutics, Aeglea BioTherapeutics